DongKookPharmaceuticalCo.,Ltd.

086450KOSDAQPharmaceuticals

DongKookPharmaceuticalCo.,Ltd. (086450, KOSDAQ) reported KRW 927bn revenue in 2025.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
20237316749840576Consolidated
20248128062953679Consolidated
202592797741,063764Consolidated

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
20239.1%6.7%68.6%8.5%
20249.9%7.7%71.2%9.2%
202510.4%8%71.9%9.7%

Revenue moved 26.8% between 2023 and 2025.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 893bn
Close priceKRW 19,740
Listed shares45,230,420
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

Workforce — a side measure, not the main one

Employees (2025)1,306
Women475 (36.4%)
Average tenure6.2 years
Annual pay, menKRW 76,000,000
Annual pay, womenKRW 53,000,000
Pay ratio, women to men69.7%

Other companies in Pharmaceuticals

181 listed companies file under this classification. Showing 12.

See the whole Pharmaceuticals list →